Human Vaccines &amp; Immunotherapeutics: News

Riedmann, Eva M.

doi:10.4161/hv.26237

Cited by 2 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study group consisted of 500 patients undergoing haematopoietic cell transplant (HCT). Previous phases have produced very promising results of action of this vaccine [39]. VCL-CT02 / Towne is a prime booster vaccine consisting of a trivalent vaccine with DNA with plasmids encoding pp65, IE1 and gB.…”

Section: Treatment and Preventionmentioning

confidence: 99%

Cytomegalovirus (CMV) – a new prospect for prevention

Polz‐Dacewicz¹,

Fołtyn²,

Macieląg³

et al. 2014

J Pre Clin Clin Res.

View full text Add to dashboard Cite

Human cytomegalovirus (HCMV), a member of the Betaherpesvirinae subfamily of the Herpesviridae family, is a widespread pathogen. CMV is a virus usually completely harmless to healthy people; nevertheless, it is still a major cause of morbidity and mortality in immunocompromised individuals, such as organ transplant recipients (also haematopoietic stem cell transplantation) and AIDS patients. Furthermore, is a common cause of congenital infections. So far, it is not possible to take effective prevention activities, although there are high expectations in finding an effective vaccine. Understanding the detailed construction of the virus helped to create exactly harmless virus strains used for research. Progress in genetics and biotechnology allowed the carrying out of changes in the virus genome. Today, we know the different parts of the DNA code, are able to modify them, delete, and add inserts. All these actions bring us closer to achieving the objective of an effective and safe vaccine. The presented study shows the results of many different studies and attempts to find an effective vaccine against HCMV. The development direction of research is broad and includes various activities with the use of subunit vaccines, DNA vaccines, peptides and vaccines using the vectors. Some preparations are just at the beginning of a long journey for the registration of an acceptable vaccine, while others have entered into the last phase of clinical trials.

show abstract

Section: Treatment and Preventionmentioning

confidence: 99%

Cytomegalovirus (CMV) – a new prospect for prevention

Polz‐Dacewicz¹,

Fołtyn²,

Macieląg³

et al. 2014

J Pre Clin Clin Res.

View full text Add to dashboard Cite

show abstract

“…Recently, a commercial dengue vaccine was approved by the FDA. It delivers only very partial protection (56% reduction in cases) against dengue fever in the vaccinated children ( 17 ). But more important questions remain.…”

Section: New Evidencementioning

confidence: 99%

Pediatric Infectious Diseases: Getting Research Evidence into Practice and Generation of New Evidence

Rostenberghe

2014

Front. Pediatr.

View full text Add to dashboard Cite

Human Vaccines & Immunotherapeutics: News

Cited by 2 publications

References 7 publications

Cytomegalovirus (CMV) – a new prospect for prevention

Cytomegalovirus (CMV) – a new prospect for prevention

Pediatric Infectious Diseases: Getting Research Evidence into Practice and Generation of New Evidence

Contact Info

Product

Resources

About